Discontinued — last reported Q3 '22
Amphenol Acquisitions decreased by 7.1% to $289.00M in Q3 2025 compared to the prior quarter. Over 3 years (FY 2021 to FY 2024), Acquisitions shows relatively stable performance with a -1.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.35B | $0.00 | $694.40M | $0.00 | $74.50M | $213.70M | $0.00 | $113.20M | $0.00 | $179.40M | $677.80M | $0.00 | $2.10B | $0.00 | $56.60M | $2.17B | $311.00M | $289.00M |
| QoQ Change | — | -100.0% | — | -100.0% | — | +186.8% | -100.0% | — | -100.0% | — | +277.8% | -100.0% | — | -100.0% | — | >999% | -85.7% | -7.1% |
| YoY Change | — | — | — | — | -94.5% | — | -100.0% | — | -100.0% | -16.1% | — | -100.0% | — | -100.0% | -91.6% | — | -85.2% | — |
We use cookies for analytics. See our Privacy and Cookie Policy.